The statistic depicts the average p/e (price-to-earnings) ratios in U.S. big pharma and big biotech in 2005 and 2010. In 2005, the average p/e ratio in the U.S. biotech sector was 16.

Legend Biotech current p/s ratio as of June 23, 2025 is 11.36. Legend Biotech average p/s ratio for 2024 was 30.86, a 48.17% decline from 2023. Legend Biotech average p/s ratio for 2023 was 59.54, a 2.69% decline from 2022. Legend Biotech average p/s ratio for 2022 was 57.98, a 11.22% increase from 2021. P/s ratio can be defined as the price to sales or PS ratio is calculated by taking the latest closing price and dividing it by the most recent sales per share number. The PS ratio is an additional way to assess whether a stock is over or under valued and is used primarily in cases where earnings are negative and the PE ratio cannot be utilized.

The price to earnings ratio is a measurement often used to determine stock valuation. In short, P/E is used to measure what the market is willing to pay for a company based on its earnings. The trailing P/E for healthcare product companies operating in the health and pharmaceuticals market was approximately 147.3. This meant that an investor would be willing to pay 147.3 dollars for every one dollar made through earnings. Another formula that is used by investors to measure the value of an industry or potential target company for acquisition is the enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA).